The cardiomyopathies market is set to grow from $1.6 billion in 2021 to $5.2 billion in 2031 across the seven major markets (7MM: USA, 5EU (France, Germany, Italy, Spain, and the UK), and Japan) at a compound annual growth rate (CAGR) of 12.4%.
Data and analytics company GlobalData notes that growth in the USA, 5EU and Japan will largely be driven by late-stage pipeline products.
According to GlobalData’s report, ‘ Cardiomyopathies Market Size and Trend Report, 2021-2031’, cardiomyopathies are most often managed with generic drugs such as beta blockers, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze